ClinicalTrials.gg
CompletedNCT06575933Updated Feb 11, 2026

A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

A Phase 1 interventional study of Calderasib and Midazolam in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Enrollment
79th of 88
28 · median 149
Started
2024
with 7 others
Phase 1
19 of 91
none open now
Registered
81st of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 79th largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2024, is one of 19 in phase 1, and was the 81st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is medically healthy with no medical history, physical examination, laboratory profiles, vitals signs, and (ECGs)
  • Has a (BMI) ≥18 and ≤32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study
  • Has a history or presence of or idiosyncratic reaction to the study drugs or related compounds
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Period 1: Midazolam and Digoxin

    Participants will receive a single oral dose of midazolam and a single oral dose of digoxin on Day 1.

    Drug: Midazolam · Drug: Digoxin

  • Experimental
    Period 2: Calderasib, Midazolam, and Digoxin

    A washout period of at least 10 days will occur following midazolam and digoxin dosing in Period 1 and the first calderasib dosing in Period 2. Participants will receive calderasib once daily on Days 1 through Day 15 with a single oral dose of midazolam on Days 1, 6, and 14 and a single oral dose of digoxin on Days 1 and 11.

    Drug: Calderasib · Drug: Midazolam · Drug: Digoxin

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Midazolam

    Blood samples will be collected to determine the AUC0-inf of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Midazolam

    Blood samples will be collected to determine the AUC0-last of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  3. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hr) of Midazolam

    Blood samples will be collected to determine the AUC0-24hr of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  4. Maximum Plasma Concentration (Cmax) of Midazolam

    Blood samples will be collected to determine the Cmax of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Time to Maximum Plasma Concentration (Tmax) of Midazolam

    Blood samples will be collected to determine the Tmax of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  6. Apparent Terminal Half-life (t1/2) of Midazolam

    Blood samples will be collected to determine the t1/2 of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  7. Apparent Clearance (CL/F) of Midazolam

    Blood samples will be collected to determine the CL/F of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  8. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Midazolam

    Blood samples will be collected to determine the Vz/F of midazolam.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  9. AUC0-Inf of Digoxin

    Blood samples will be collected to determine the AUC0-inf of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  10. AUC0-Last of Digoxin

    Blood samples will be collected to determine the AUC0-last of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  11. AUC0-24hr of Digoxin

    Blood samples will be collected to determine the AUC0-24hr of digoxin.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  12. Cmax of Digoxin

    Blood samples will be collected to determine the Cmax of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  13. Tmax of Digoxin

    Blood samples will be collected to determine the Tmax of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  14. t1/2 of Digoxin

    Blood samples will be collected to determine the t1/2 of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  15. CL/F of Digoxin

    Blood samples will be collected to determine the CL/F of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  16. Vz/F of Digoxin

    Blood samples will be collected to determine the Vz/F of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

Secondary outcomes

  1. AUC0-24hr of Calderasib

    Blood samples will be collected to determine the AUC0-24hr of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  2. AUC0-Last of Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  3. Cmax of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  4. C24 of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Tmax of Calderasib

    Blood samples will be collected to determine the Tmax of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  6. t1/2 of Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  7. Cmax Accumulation Ratio of Calderasib

    Blood samples will be collected to determine the Cmax accumulation ratio of calderasib. The accumulation ratio is the ratio of Predose Cmax to the 24 hour Cmax

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  8. AUC0-24 Accumulation Ratio of Calderasib

    Blood samples will be collected to determine the AUC0-24 accumulation ratio of calderasib. The accumulation ratio is the ratio of Predose AUC0-24 to the 24 hour AUC0-24.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  9. Amount of Drug Excreted in Urine from Time 1 to Time 2 (Aet1-t2) of Digoxin

    Urine samples will be collected to determine the Aet1-t2 of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  10. Total Amount of Drug Excreted in Urine (Ae) of Digoxin

    Urine samples will be collected to determine the Ae of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  11. Fraction of Unchanged Digoxin in Urine (Fe)

    Urine samples will be collected to determine the Fe of digoxin.

    Time frame: Predose and at designated timepoints up to 120 hours postdose

  12. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 1 month

  13. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 1 month

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2024, 1 month.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 1 month is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Sep 3, 2024
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575933
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Sep 3, 2024
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Last update
Feb 11, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Digoxin

Start the discussion